THISTLE BIOLABS JOURNAL • EMERGING RESEARCH
Zenagamtide — previously widely referred to as amycretin — is an emerging example of a single peptide designed to engage both GLP-1 and amylin receptors.
At a glance
- Zenagamtide is also known as amycretin.
- It is designed as a unimolecular GLP-1 and amylin receptor agonist.
- Novo Nordisk reported positive Phase 2 data in June 2026.
- The company said the programme will advance into Phase 3; the molecule remains investigational.
Research-use note: Zenagamtide is investigational. This article is an educational summary of research developments, not a treatment or personal-use guide.
One molecule, two signalling systems
The defining feature of zenagamtide is its unimolecular design. Rather than combining two separate compounds, the research programme uses one peptide engineered to engage both GLP-1 and amylin receptors.
That makes it scientifically different from fixed-dose combinations such as CagriSema, where two distinct active molecules are administered together.
Why GLP-1 and amylin?
GLP-1 and amylin participate in different metabolic signalling pathways. Studying both within one molecule creates questions around receptor balance, pharmacokinetics, pathway interaction and whether a single molecular architecture can produce a predictable dual-receptor profile.
For laboratory research, this makes zenagamtide a useful example of modern multi-target peptide design.
What happened in June 2026
Novo Nordisk announced Phase 2 results for zenagamtide at the American Diabetes Association Scientific Sessions in June 2026. The company described statistically significant glycaemic effects in adults with type 2 diabetes and said the programme would advance into Phase 3.
The announcement is important for the development programme, but the regulatory status remains unchanged: zenagamtide is investigational.
Why naming matters
Emerging compounds often become known by development codes or early names before a programme settles on a later name. In this case, “amycretin” and “zenagamtide” refer to the same investigational programme.
For researchers and procurement teams, keeping aliases connected prevents duplicate records, literature-search gaps and confusion when comparing older and newer sources.
What researchers should watch next
- Phase 3 trial design and programme expansion.
- More detailed receptor-pharmacology publications.
- Comparisons between unimolecular dual agonism and fixed-dose combinations.
- Longer-term pharmacokinetic and safety data.
- How nomenclature is standardised across future publications.
Zenagamtide is worth watching because it reflects a broader shift in peptide science: designing one molecule to coordinate multiple signalling pathways.
Source: Novo Nordisk’s June 2026 zenagamtide Phase 2 announcement.
Related pathway research
Explore related amylin and GLP-1 research
Zenagamtide is not stocked by Thistle BioLabs. The links below are related pathway research materials, not equivalent compounds.
Cagrilintide 10mg — related amylin pathway research material
Cagrilintide & amylin research in 2026
GLP-1 research overview
Browse metabolic pathway research materials